Small cell carcinoma (SCC) of the esophagus is an aggressive tumor which behaves biologically like its pulmonary counterpart. Since standard chemotherapy produces few long-term survivors, high-dose chemotherapy regimens with autologous progenitor cell support have been investigated to improve outcomes. Although these strategies have demonstrated improved response rates, overall survival has not been significantly impacted. Here, we report a unique case of a patient with stage IV SCC of the esophagus who underwent high-dose chemotherapy followed by syngeneic bone marrow transplantation. He remains disease-free 38 months post transplant with minimal long-term sequelae. Keywords: small cell carcinoma; esophageal small cell carcinoma; syngeneic transplantation; high-dose chemotherapy; bone marrow transplantation Small cell carcinoma (SCC) is an aggressive tumor that usually arises in the lung but can infrequently originate in other organs.
Small cell carcinoma (SCC) is an aggressive tumor that usually arises in the lung but can infrequently originate in other organs. 1 First reported by McKeown, 2 small cell carcinoma of the esophagus has now been reported in 230 patients. 3 Similar to pulmonary SCC, esophageal SCC is an aggressive cancer associated with short median survival times. In part because of their rapid growth, these tumors are highly chemoresponsive but, unfortunately, rarely curable. [3] [4] [5] In pulmonary SCC, more than 40 trials have been published utilizing high-dose chemotherapy with either autologous bone marrow transplantation or peripheral blood stem cell rescue. 6 Although certain subgroups may seem to benefit from this approach, overall the results have been no better than standard chemotherapy. [7] [8] [9] [10] While complete response rates with high-dose therapy are reported in 50% to 90% of patients, almost all relapse within the first 12 months and long-term survivors are rare. [11] [12] [13] Several factors may account for the short survival and high relapse rate in these trials including advanced patient age at transplantation, co-morbid illness, bulky disease at transplantation, and multidrug resistance.
14 Also, it is likely that many patients were reinfused with tumor contaminated marrow at the time of transplant. 15, 16 We report here the first case of esophageal SCC treated with induction chemotherapy followed by intensive therapy with syngeneic bone marrow transplant from an identical twin donor.
Case report
A 48-year-old Caucasian man presented with right upper quadrant pain of 3 weeks duration. He was in otherwise excellent health. At the age of 23 he began smoking a pipe and switched to a pack per day of cigarettes several years later which he continued until presentation. Computerized tomography (CT) scanning of the chest, abdomen, and pelvis demonstrated multiple liver lesions up to 3 cm in diameter and no other abnormalities. Bronchoscopy was unrevealing but esophagogastroduodenoscopy (EGD) demonstrated small cell carcinoma in the distal one-third by biopsy. Needle biopsy of one of the liver lesions confirmed metastatic small cell carcinoma. The patient had an identical twin brother with no contraindications to bone marrow donation.
The patient began an induction regimen consisting of cisplatinum 100 mg/m 2 intravenously day 1 and etoposide 100 mg/m 2 intravenously days 1-3 every 21 days for six cycles. By CT exam after cycle 6, all disease had disappeared except for one 3 cm lesion in the liver. Two cycles of highdose cyclophosphamide (Cytoxan; Mead Johnson, Princeton, NJ, USA) were then administered at 2000 mg/m 2 for two doses separated by 12 h 1 week apart. This resulted in reduction of the remaining liver lesion to 1.5 cm.
After confirming that the patient's twin brother was in fact HLA identical, bone marrow harvesting was carried out using standard technique.
Three weeks after the last cycle of cyclophosphamide chemotherapy, the patient was admitted to the University of California San Diego Medical Center in La Jolla and the high-dose preparative regimen was administered. The regimen was modified from STAMP I 17 18 On day 0 and day +1 syngeneic bone marrow was infused. The hospital course was complicated by febrile neutropenia which responded to antibiotics and supportive measures. Engraftment occurred by day 14. CT scans performed 35 days after engraftment demonstrated complete remission with no evidence of visible disease.
No signs of graft-versus-host disease (GVHD) were ever detected but the treatment was associated with grade III peripheral neuropathy involving the lower extremities. The patient has been followed for 38 months and remains disease-free.
Discussion
This is the first reported case of a syngeneic bone marrow transplantation for SCC originating from any organ. With conventional chemotherapy the chances of relapse at 3 years would have been over 90%, yet the patient remains disease-free 3 years after treatment. The fact that this therapy was successful raises several important issues regarding transplantation in these tumors.
Since the biology and treatment response of pulmonary and extrapulmonary SCC is similar, it is useful to consider them together when examining the reasons that high-dose chemotherapy has been associated with such disappointing results. 3, 6 Initial responsiveness to chemotherapy followed by an almost universal tendency to relapse would suggest the existence of a heterogenous population of malignant cells possessing resistance to cytotoxic chemotherapy. 10 Strategies to overcome chemoresistance have included the use of multiple noncross-resistant drugs delivered at the limit of their dose intensity. 9, 19 The STAMP I regimen employed in this patient is an excellent example of this strategy and has been used successfully as a preparative regimen for autotransplantation in pulmonary SCC. 10 One attractive feature of STAMP I is the inclusion of BCNU which penetrates the blood-brain barrier potentially decreasing the chances of central nervous system failure.
Another important reason for relapse after autotransplantation is contamination of infused bone marrow with occult tumor cells. Using sensitive techniques, up to 70% of pulmonary SCC patients will demonstrate bone marrow tumor involvement. 15 This problem is also encountered with peripheral blood stem cell rescue. 16 We were able to avoid this issue entirely by the use of syngeneic marrow which underscores the importance of rescuing the patient from high-dose therapy with a tumor-free stem cell product.
In summary, although this represents a rare instance where a small cell cancer patient was fortunate enough to have an identical twin marrow donor, we have demonstrated the feasibility of this approach. As technical advances, such as CD34-positive stem cell collection, enhance the ability of autologous transplantation to deliver a tumor-depleted stem cell produce and as advances, such as submyeloablation regimens, reduce the morbidity and mortality of allogenic transplantation, the role of high-dose therapy in pulmonary and extrapulmonary SCC should be redefined.
